Gerardo Olivera, MD
Psychiatry · Stuart, FLNPI 1245250505
Payments from drug & device makers
Across 524 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$1K
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$916
- Neurocrine Biosciences, Inc.$677
- plus $5K from 22 others
What the payments were for
- Food & beverage$11,89798%
- Education$1992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $2,256 |
| Otsuka America Pharmaceutical, Inc. | 48 | $1,387 |
| Johnson & Johnson | 46 | $1,321 |
| Teva Pharmaceuticals USA, Inc. | 21 | $1,030 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $916 |
| Neurocrine Biosciences, Inc. | 40 | $677 |
| Sunovion Pharmaceuticals Inc. | 47 | $658 |
| Lundbeck LLC | 37 | $611 |
| Alkermes, Inc. | 29 | $573 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $443 |
| Vanda Pharmaceuticals Inc. | 15 | $368 |
| Corium, LLC | 16 | $343 |
| Neuronetics, Inc. | 4 | $270 |
| E.r. Squibb & Sons, L.L.C. | 9 | $242 |
| Axsome Therapeutics, Inc. | 13 | $241 |
| Supernus Pharmaceuticals, Inc. | 7 | $131 |
| Shire North American Group Inc | 10 | $114 |
| Adlon Therapeutics L.p. | 6 | $101 |
| Almatica Pharma LLC | 4 | $88 |
| Ironshore Pharmaceuticals Inc. | 3 | $71 |
| Eisai Inc. | 4 | $68 |
| Tris Pharma Inc | 2 | $42 |
| Merck | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Livanova USA, Inc. | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$603
- VRAYLAR$504
- CAPLYTA$479
- AUSTEDO$367
- SPRAVATO$213
- NEUROSTAR TMS THERAPY SYSTEM$172
- Austedo XR$122
How this compares
$12,096 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 99 | $393,802 |
| Austedo XrDeutetrabenazine | 34 | $184,513 |
| VraylarCariprazine Hcl | 33 | $52,273 |
| Invega SustennaPaliperidone Palmitate | 17 | $44,254 |
| RexultiBrexpiprazole | 19 | $41,917 |
| VyvanseLisdexamfetamine Dimesylate | 84 | $35,723 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $20,011 |
| OzempicSemaglutide | 18 | $18,605 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 433 | $11,823 |
| Aripiprazole | 124 | $9,003 |
| Lisdexamfetamine Dimesylate | 37 | $7,129 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 58 | $6,615 |
| Clonazepam | 724 | $6,317 |
| Dyanavel XrAmphetamine | 11 | $5,562 |
| Oxcarbazepine | 87 | $5,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna | $1,321 | $438,056116 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,030 | $184,51334 claims |
| AbbVieVraylar | $2,256 | $52,27333 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,387 | $41,91719 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $443 | $35,72384 claims |
| Tris Pharma IncDyanavel Xr | $42 | $5,56211 claims |
| Almatica Pharma LLCSertraline Hcl | $88 | $1,836303 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Stuart
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.